Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mycenax BiotechROCO:4726 -4.67%43 PB Ratio is 3.18 as of Jul. 18, 2026, which is 2% above its 10-year median of 3.12. GuruFocus rates ROCO:4726 with a GF Score™ of 43/100 and a GF Value™ of NT$47.88 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Mycenax Biotech ranks worse than 55.91% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-18), Mycenax Biotech's share price is NT$24.50. Mycenax Biotech's Book Value per Share for the quarter that ended in Dec. 2025 was NT$7.72. Hence, Mycenax Biotech's PB Ratio of today is 3.18.
Good Sign:
Mycenax Biotech Inc stock PB Ratio (=3.32) is close to 2-year low of 3.11.
The historical rank and industry rank for Mycenax Biotech's PB Ratio or its related term are showing as below:
ROCO:4726'
s PB Ratio Range Over the Past 10 Years
Min: 1.4 Med: 3.12 Max: 7.04
Current: 3.16
During the past 13 years, Mycenax Biotech's highest PB Ratio was 7.04. The lowest was 1.40. And the median was 3.12.
ROCO:4726's PB Ratio is ranked worse than 55.91% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs ROCO:4726: 3.16
During the past 12 months, Mycenax Biotech's average Book Value Per Share Growth Rate was -21.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Mycenax Biotech was 68.60% per year. The lowest was -20.10% per year. And the median was -4.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mycenax Biotech PB Ratio Related Terms
Mycenax Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Mycenax Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4726 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Mycenax Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mycenax Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mycenax Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mycenax Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mycenax Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mycenax Biotech (ROCO:4726) has a PB Ratio of 3.18 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mycenax Biotech and its competitors. This is near median its historical median of 3.12. Over the past decade, Mycenax Biotech's PB Ratio has ranged from 1.40 to 7.04. According to the industry distribution chart, Mycenax Biotech ranks #686 out of 1227 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Mycenax Biotech's PB Ratio too high?
Mycenax Biotech's current PB Ratio of 3.18 is near median its 10-year median of 3.12. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 7.04. The Biotechnology industry median PB Ratio is 2.82. Mycenax Biotech's value of 3.18 is 12.8% above this industry median. Based on the distribution chart, Mycenax Biotech ranks #686 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mycenax Biotech ranks #686 out of 1227 companies for PB Ratio. This places Mycenax Biotech in the lower half of its industry. The industry median PB Ratio is 2.82. Mycenax Biotech's value of 3.18 is 12.8% above this benchmark. Historically, Mycenax Biotech's own PB Ratio has ranged from 1.40 to 7.04 over the past decade. While the company's 10-year median is 3.12 vs. the industry median of 2.82, Mycenax Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mycenax Biotech's current PB Ratio of 3.18 is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mycenax Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mycenax Biotech's current PB Ratio is 3.18, which is near median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current PB Ratio is 3.18, which is near median its 10-year median of 3.12 and 12.8% above the Biotechnology industry median of 2.82. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current PB Ratio is 3.18 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?
Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued.
The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88.
GuruFocus considers Mycenax Biotech to be Possible Value Trap.
Key valuation signals for ROCO:4726:
PB Ratio: 3.18 (near median its 10-year median of 3.12)
GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
Industry Position: 12.8% above the Biotechnology median (#686 of 1227)
No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score
Get the complete analysis for ROCO:4726
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4726 has been successfully added to your 
